Review article: the diagnosis and management of alcoholic hepatitis.
BACKGROUND
Alcoholic hepatitis is a severe, cholestatic liver disease occurring in patients with alcohol abuse. Mortality is substantial; however, therapies may improve clinical outcomes.


OBJECTIVE
To provide an updated review of the epidemiology, diagnosis, staging and treatment of alcoholic hepatitis.


METHODS
A MEDLINE literature search was performed to identify pertinent articles. Relevant clinical abstracts were also reviewed.


RESULTS
Severe alcoholic hepatitis occurs in a small fraction of patients who abuse alcohol. The 28-day mortality ranges from 30% to 50% in most series. Diagnosis is generally based on clinical features, with a limited role for liver biopsy. Beneficial treatment options include alcohol abstinence and nutritional therapy. Despite variable results in clinical trials, corticosteroids and pentoxifylline appear to provide moderate survival benefit. Anti-tumour necrosis factor agents and antioxidants have not proven beneficial, and should be limited to clinical trials. Liver transplant is not a frequent option given the active or recent alcohol use.


CONCLUSIONS
Severe alcoholic hepatitis is a clinically-diagnosed condition associated with significant mortality. Alcohol abstinence and nutritional therapy have been associated with improved clinical parameters and should be considered in all patients. Corticosteroid therapy and pentoxifylline therapy appear to show moderate survival benefit and should be considered as first-line therapeutic agents.
Section of Hepatology, Rush University Medical Center, Chicago, IL 60612, USA. stanley_m_cohen@rush.edu
S M
SM
Cohen
J
J
Ahn
D045930:Anabolic Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use; D006519:Hepatitis, Alcoholic / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D006801:Humans; D016031:Liver Transplantation; D018529:Nutritional Support; D010431:Pentoxifylline / Q000627:therapeutic use*; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D011239:Prednisolone / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013695:Temperance; D014409:Tumor Necrosis Factor-alpha
D045930:Anabolic Agents; D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D010726:Phosphodiesterase Inhibitors; D014409:Tumor Necrosis Factor-alpha; D011239:Prednisolone; D010431:Pentoxifylline